在炎症性肠病患者中使用补充和替代疗法
1School of Medical, Indigenous and Health Sciences, University of Wollongong, Wollongong, NSW 2522, Australia.
International journal of environmental research and public health
|September 28, 2024
概括
补充和替代药物 (CAMs) 被澳大利亚炎症性肠病 (IBD) 患者广泛使用. 许多患者发现CAM从业者有帮助,寻求改善福祉和长期IBD管理.
科学领域:
- 胃肠病学 胃肠病学
- 综合医学是一个整体的医学.
- 公共卫生 公共卫生
背景情况:
- 补充和替代药物 (CAM) 经常被诊断为炎症性肠病 (IBD) 的个人讨论和使用.
- 了解IBD患者对CAM使用的模式和看法对于全面的患者护理至关重要.
- 关于CAM在IBD管理中的有效性和安全性的现有研究仍然有限,影响了医疗保健提供者的讨论.
研究的目的:
- 研究澳大利亚患有炎症性肠病 (IBD) 的澳大利亚人使用补充和替代医学的流行率和模式.
- 探索患者对CAM从业人员和IBD管理产品有用性的看法.
- 确定与IBD人口中CAM使用相关的人口因素.
主要方法:
- 一项采用匿名在线调查的横截面研究,通过IBD特定的社交媒体平台分发.
- 定量数据分析包括描述性统计,奇平方测试和二进制物流回归.
- 使用简单的主题分析分析了定性自由文本响应.
主要成果:
- 在123名受访者中,很大一部分表示使用CAM,其中针和手术治疗服务很常见.
- 维生素,益生菌和草药是最常用的CAM产品,通常用于感知健康改善或IBD管理.
- 女性更有可能接触CAM从业者 (OR 12.6). 虽然医生是主要的信息来源,但人们表达了对传统治疗的不满以及对整体护理的渴望.
结论:
- 在患有IBD的澳大利亚人中,CAM使用很普遍,患者经常认为这些疗法是有益的.
- 高利用率凸显了传统IBD护理中的潜在差距,患者寻求更全面的方法.
- 患者和医疗保健提供者之间关于CAM使用的加强沟通对于综合和以患者为中心的IBD管理至关重要.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
143
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
323
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
323
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
97
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
97
Drugs for Treatment of Ulcerative Colitis in IBD
128
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
128
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117


